Intra-Cellular Therapies Inc (ITCI)
72.20
-0.46
(-0.64%)
USD |
NASDAQ |
May 02, 11:31
Intra-Cellular Therapies Net Income (Quarterly): -28.58M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -28.58M |
| September 30, 2023 | -24.26M |
| June 30, 2023 | -42.78M |
| March 31, 2023 | -44.05M |
| December 31, 2022 | -44.03M |
| September 30, 2022 | -53.51M |
| June 30, 2022 | -86.60M |
| March 31, 2022 | -72.12M |
| December 31, 2021 | -85.73M |
| September 30, 2021 | -76.91M |
| June 30, 2021 | -68.74M |
| March 31, 2021 | -52.74M |
| December 31, 2020 | -60.70M |
| September 30, 2020 | -55.18M |
| June 30, 2020 | -63.71M |
| March 31, 2020 | -47.41M |
| December 31, 2019 | -40.58M |
| September 30, 2019 | -34.86M |
| June 30, 2019 | -37.44M |
| March 31, 2019 | -34.84M |
| December 31, 2018 | -40.75M |
| September 30, 2018 | -41.52M |
| Date | Value |
|---|---|
| June 30, 2018 | -37.38M |
| March 31, 2018 | -35.48M |
| December 31, 2017 | -30.21M |
| September 30, 2017 | -22.87M |
| June 30, 2017 | -17.76M |
| March 31, 2017 | -26.93M |
| December 31, 2016 | -27.48M |
| September 30, 2016 | -30.27M |
| June 30, 2016 | -30.83M |
| March 31, 2016 | -27.84M |
| December 31, 2015 | -28.83M |
| September 30, 2015 | -32.16M |
| June 30, 2015 | -21.51M |
| March 31, 2015 | -22.29M |
| December 31, 2014 | -15.20M |
| September 30, 2014 | -6.416M |
| June 30, 2014 | -4.534M |
| March 31, 2014 | -4.543M |
| December 31, 2013 | -8.041M |
| September 30, 2013 | -4.912M |
| June 30, 2013 | -0.0109M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-86.60M
Minimum
Jun 2022
-24.26M
Maximum
Sep 2023
-53.68M
Average
-52.74M
Median
Mar 2021
Net Income (Quarterly) Benchmarks
| Johnson & Johnson | 3.255B |
| Insmed Inc | -186.06M |
| Vertex Pharmaceuticals Inc | 968.80M |
| Fate Therapeutics Inc | -44.12M |
| ADMA Biologics Inc | -17.64M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 131.51M |
| Total Expenses (Quarterly) | 165.60M |
| EPS Diluted (Quarterly) | -0.30 |
| Enterprise Value | 6.537B |
| Gross Profit Margin (Quarterly) | 91.86% |
| Profit Margin (Quarterly) | -21.73% |
| Earnings Yield | -2.02% |
| Normalized Earnings Yield | -2.022 |